Results 181 to 190 of about 22,884 (253)

An integrative neuropharmacological review of Huntington's disease challenges and the role of novel formulations in addressing pharmacological‒pharmaceutical limitations. [PDF]

Front Pharmacol
Senousy MA, Eid AH, Zaki MB, A Abd-Elmawla M, Ghaiad HR, El-Shiekh RA, Ahmed S, Khalifa HO.   +7 more
europepmc   +1 more source

Opportunities and challenges in protein structure prediction

Quantitative Biology, Volume 14, Issue 2, June 2026.
Abstract Deep learning methods, particularly exemplified by AlphaFold2, have revolutionized the field of protein structure prediction—an achievement recognized by the 2024 Nobel Prize in Chemistry awarded to its core developers. Despite this remarkable achievement, the broader protein folding problem is far from solved. Key challenges—each representing
Wenkai Wang, Baoquan Su, Chenxiao Xiang, Jianyi Yang   +3 more
wiley   +1 more source

Coverage with evidence development for medicines with insufficient evidence of clinical benefit: experience from the Netherlands. [PDF]

Int J Technol Assess Health Care
Versteeg JW, Stam N, Mantel-Teeuwisse AK, Timmers L, Goettsch W, Leopold C.   +5 more
europepmc   +1 more source

When Public Health Becomes the Weapon: Current and Prospective Consequences of the Genocide in Gaza

World Medical &Health Policy, Volume 18, Issue 2, June 2026.
ABSTRACT Catastrophic humanitarian conditions during the 2023–2025 genocide in Gaza have caused a public health crisis of exceptional magnitude. This article summarizes key short‐ and long‐term health consequences for Gaza's civilian population and outlines priorities for recovery.
Therese Alexandra Evald, Nanna Gram Ahlmark, Clara Barfod Parellada, Andreea Micula, Caroline Klint Johannesen, Dana Bdier, Fayez Mahamid, Hilde Lausund, Jane Brandt Sørensen, Maha Aon, Majd Qannita, Maren Johanne Heilskov Rytter, Nanna Maaløe, Nina Jøranson, Sara Aakre Faradonbeh, Vibeke Brix Christensen, Waseem Alzaanin, Sigurd Lauridsen, Helle Timm, Frederik Schou‐Juul   +19 more
wiley   +1 more source

Advances in Cell and Gene Therapy for Rare Disease Treatment. [PDF]

Int J Stem Cells
Baek HJ, Nam Y, Rim YA, Ju JH.
europepmc   +1 more source

RORA Targeting PRNP Modulates Age‐Related Cataract via Activation Oxidative Injury‐Induced Cellular Senescence and Apoptosis of Lens Epithelial Cells

Aging Cell, Volume 25, Issue 6, June 2026.
The molecular mechanisms of RORA targeting PRNP activate oxidative injury‐induced cellular senescence and apoptosis of lens epithelial cells. Current research confirms that the transcription factor RORA targets PRNP, exacerbating cellular senescence and apoptosis of LECs (Figure 7).
Yue Zou, Wanqian Li, Jiaojiao Zhang, Chao Cen, Wanqiu Zheng, Ruonan Li, Hong Cheng, Liang Liang, Juan Kang, Wenjuan Wan, Ke Hu, Shijie Zheng   +11 more
wiley   +1 more source

Pregnancies in women with rare diseases: Selected maternal and perinatal outcomes

Acta Obstetricia et Gynecologica Scandinavica, Volume 105, Issue 6, Page 1088-1095, June 2026.
Pregnancies in women with rare diseases carry substantial disease‐related (23.2%) and pregnancy‐specific (25.1%) risks. Complication rates drop markedly when conditions are stable before conception. Abstract Introduction Rare diseases (RD) are characterized by chronicity and may be associated with reduced life expectancy and quality of life.
Philipp Kosian, Kristin Niederhöfer, Elena Jost, Ulrich Gembruch, Tim Bender, Lorenz Grigull, Waltraut Maria Merz   +6 more
wiley   +1 more source

How to evaluate rare disease policy effectiveness based on policy modeling consistency (PMC) index model: A quantitative assessment of policy implementation in China. [PDF]

Intractable Rare Dis Res
Zhao Y, Zhang X, He D, Li Y, Dong R, Gu Y, Xie J.   +6 more
europepmc   +1 more source

Real‐world treatment patterns and outcomes among patients with immune thrombocytopenia (ITP) who switched treatment from eltrombopag or romiplostim to avatrombopag in the United States: Results from the REAL‐AVA 3.5 study

British Journal of Haematology, Volume 208, Issue 6, Page 2185-2193, June 2026.
Summary Real‐world data on treatment response after switching between thrombopoietin receptor agonists are limited for patients with immune thrombocytopenia (ITP). The objective of this study is to describe treatment patterns and outcomes in patients with primary ITP who switched from eltrombopag (ELT) or romiplostim (ROMI) to avatrombopag (AVA).
Caroline Piatek, Abiola Oladapo, Scott Kolodny, Michael Vredenburg, Sarah Lucht, Emily Bland, Prathamesh Pathak, Bruce Feinberg, Hillary Maitland   +8 more
wiley   +1 more source

Modulation of KATP channels by diazoxide preserves mitochondrial function and barrier integrity under staurosporine‐induced epithelial stress

British Journal of Pharmacology, Volume 183, Issue 12, Page 3213-3233, June 2026.
Background and Purpose Intestinal barrier dysfunction caused by mitochondrial stress, oxidative damage and apoptosis, are hallmarks of dysbiosis‐associated gastrointestinal (GI) disorders. Staurosporine causes downstream features of dysbiosis‐induced epithelial damage.
Fatima Maqoud, Eleonora Malerba, Simona Drago, Antonella Orlando, Domenica Mallardi, Nicoletta De Lucia, Marina Antonacci, Annamaria Di Turi, Domenico Tricarico, Francesco Russo   +9 more
wiley   +1 more source